William D. Turner - Mar 18, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role: Chief Reg & Tech Ops Officer
Signature: /s/ Mary Christina Thomson, Attorney-In-Fact for William D. Turner
Stock symbol: SRRA
Transactions as of: Mar 18, 2022
Transactions value $: -$2,500
Form type: 4
Date filed: 3/22/2022, 04:15 PM
Previous filing: Mar 17, 2022
Next filing: Apr 7, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRRA	Common Stock	Options Exercise	$1.21K	+100		$12.05	100	Mar 18, 2022	Direct
transaction	SRRA	Common Stock	Sale	-$3.71K	-100	-100%	$37.05	0	Mar 18, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SRRA	Stock Option (Right to Buy)	Options Exercise	$0	+100		$0.00^*	0	Mar 18, 2022	Common Stock	100	$12.05	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2021. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
F2	On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.